STOCK TITAN
  1. Home
  2. Sec-filings
  3. PFE
  4. [Form 4] PFIZER INC Insider Trading Activity

Pfizer (PFE) SVP settles stock appreciation rights with share withholdings

Filing Impact
(Very High)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Pfizer Inc. senior vice president and controller Jennifer B. D'Amico reported transactions tied to stock appreciation rights (SARs). On earn-out of these SARs, she acquired 17,558 shares of Pfizer common stock through an exercise or conversion at a reference price of $33.82 per share. In connection with the earn-out, 361 shares at $27.09 per share and 16,687 shares at $26.92 per share were withheld to cover tax obligations and the exercise price. After these tax-withholding dispositions, she directly owned 12,696 shares of Pfizer common stock. These moves reflect equity compensation settlement rather than open-market buying or selling.

Positive

  • None.

Negative

  • None.
Insider DAMICO JENNIFER B.
Role SVP & Controller
Type Security Shares Price Value
Exercise Stock Appreciation Rights 17,558 $0.00 --
Exercise Common Stock 17,558 $33.82 $594K
Tax Withholding Common Stock 361 $27.09 $10K
Tax Withholding Common Stock 16,687 $26.92 $449K
Holdings After Transaction: Stock Appreciation Rights — 0 shares (Direct); Common Stock — 29,744 shares (Direct)
Footnotes (1)
  1. The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
DAMICO JENNIFER B.
(Last) (First) (Middle)
66 HUDSON BOULEVARD EAST
ATTN: CORPORATE SECRETARY
(Street)
NEW YORK NY 10001-2192
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
PFIZER INC [ PFE ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
SVP & Controller
3. Date of Earliest Transaction (Month/Day/Year)
02/25/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/25/2026 M 17,558(1) A $33.82 29,744 D
Common Stock 02/25/2026 F 361(2) D $27.09 29,383 D
Common Stock 02/25/2026 F 16,687(3) D $26.92(4) 12,696 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Appreciation Rights $33.82 02/25/2026 M 17,558 02/25/2026 02/25/2026 Common Stock 17,558 $0.0000 0.0000 D
Explanation of Responses:
1. The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).
2. The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.
3. The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).
4. Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.
/s/ Shanice A. Reid, by power of atty, for Jennifer B. Damico 02/27/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Pfizer (PFE) report for Jennifer B. D'Amico?

Jennifer B. D'Amico exercised stock appreciation rights into 17,558 Pfizer common shares, then had 361 and 16,687 shares withheld to cover taxes and the exercise price. These transactions reflect equity award settlement, not open-market purchases or sales.

Did Pfizer (PFE) insider Jennifer B. D'Amico buy or sell shares on the open market?

The Form 4 shows no open-market buying or selling. Shares were acquired by exercising stock appreciation rights and then partially withheld to satisfy tax obligations and the exercise price, which is typical for equity compensation settlements.

How many Pfizer (PFE) shares does Jennifer B. D'Amico own after these Form 4 transactions?

Following the exercise of stock appreciation rights and related tax and exercise-price withholdings, Jennifer B. D'Amico directly owns 12,696 shares of Pfizer common stock. This figure reflects her updated direct holdings after all reported transactions on the settlement date.

What prices were used for the Pfizer (PFE) share withholdings in Jennifer B. D'Amico's Form 4?

The reported tax and exercise-price withholdings used prices of $27.09 per share for 361 shares and $26.92 per share for 16,687 shares. The stock appreciation right earn-out used a $33.82 reference price when converting into common shares.

What do the stock appreciation rights in Pfizer (PFE) insider filing represent?

The stock appreciation rights represent an earn-out of equity compensation, including dividend equivalents. Upon settlement, they were converted into 17,558 Pfizer common shares, with part of the shares withheld to pay taxes and the exercise price using a 20-day average price mechanism.